Genmab — August 2016
-
Astma er (var) i hvert fald eksklusionskriterie i dara mono fase 2 https://www.clinicaltrials.gov/ct2/show/NCT01985126?term=daratumumab+monoclonal&rank=5
-
-
Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma - http://szpiczak.org/lang/aktualnosci/komunikaty/pdf/rok_2016/Practical_considerations_dara_Moreau_Therapy_in_Practice_2016.pdf
-
Patients with known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 s (FEV1) \50 % of predicted normal, or with moderate or severe persistent asthma within the past 2 years, should not receive daratumumab. In fact, FEV1 testing should be performed for patients in whom COPD is suspected, and they must be excluded if FEV1 is \50 % of the predicted value.
-
Lidt om genterapiernes anvendelse udenfor cancer - http://medwatch.dk/Medicinal___Biotek/article8887308.ece
-
Der kommer liv i markedet efterhånden
-
Fra Finsens patientinformation vedr. Pollux: FEV (forceret ekspirationsvolumen): Hvis du har vejrtrækningsbesvær, såsom KOL
(kronisk obstruktiv lungesygdom), kan du få foretaget en undersøgelse kaldet FEV ved
screening. Undersøgelsen hjælper lægen med at forstå, hvor godt dine lunger fungerer. Til
denne undersøgelse vil du blive bedt om at tage en dyb indånding efterfulgt af en udånding
på et par sekunder i et apparat.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind